腱疾患における疼痛および可動性制限の治療におけるOSTENIL® TENDONの有効性と安全性
PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Raphaela Geiger
- 電話番号:+49 89-461483-27
- メール:geiger@trbchemedica.de
研究連絡先のバックアップ
- 名前:Veronika Mussack, Dr.
- 電話番号:+49 89-461483-43
- メール:mussack@trbchemedica.de
研究場所
-
-
-
Berlin、ドイツ、13589
- 完了
- Orthopädie am Kiesteich
-
Berlin、ドイツ、10627
- 完了
- ATOS MVZ meviva Berlin
-
Berlin、ドイツ、14197
- 完了
- Gemeinschaftspraxis Dr. Bierke
-
Potsdam、ドイツ、14482
- 完了
- Orthopädische Praxis Dr. Fischer
-
-
State of Berlin
-
Berlin、State of Berlin、ドイツ、14195
- 募集
- Orthopädisches Versorgungszentrum und Interdisziplinäres Schmerzzentrum Zehlendorf
-
コンタクト:
- Christopher Kohler, Dr. med.
- 電話番号:+49 30 81051850
- メール:kohler@ortho-zentrum-zehlendorf.de
-
Berlin、State of Berlin、ドイツ、14195
- 完了
- Orthopädische Gemeinschaftspraxis ÜBAG
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients over 18 years of age with symptomatic tendinopathy (patella tendon, peroneal tendon, medial epicondylus humeri or iliotibial band) and a recommendation for OSTENIL® TENDON treatment.
説明
Inclusion Criteria:
- Patient aged between 18 and 99 years
- Diagnosis of symptomatic tendinopathy (patella tendon, peroneal tendon, medial epicondylus humeri or iliotibial band)
- Physician's recommendation to use OSTENIL® TENDON prior to recruitment
- Signed informed consent
Exclusion Criteria:
-
Presence of any contra-indication or precautionary condition listed in the instructions for use, i.e.,
- Ascertained hypersensitivity to any of the OSTENIL® TENDON constituents
- Known pregnancy or breast feeding
- Acute trauma
-
Use of the following treatments (the given time intervals refer to the date of inclusion):
- Local* OSTENIL® TENDON or other hyaluronic acid (HA) treatment within the last 6 months
- Local* platelet-rich plasma (PRP) treatment within the last 3 months
- Local* corticosteroid treatment (without time restriction)
- Local* extracorporeal shock wave therapy (ESWT) within the last 4 weeks
- Local* phytotherapy (e.g., Traumeel®) within the last 4 weeks
- Local* surgical intervention (without time restriction)
- Systemic corticosteroid treatment within the last 4 weeks
- Repeated use of non-steroidal anti-inflammatory drugs (NSAID) and/or other analgesics within the last week
- Physiotherapy (therapeutic exercises and physical therapy), ortheses, transcutaneous electrical nerve stimulation (TENS) or acupuncture within the last week
-
Diagnosis of chronic inflammatory disease (e.g. rheumatoid arthritis, Bechterew disease, Crohn's disease, etc.) prior to inclusion
-
Participation in a clinical investigation within the last 6 months
-
Vulnerable patient (individual who is unable to fully understand all aspects of the study that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response [including persons needing legally designated representatives, illiterate persons or persons with insufficient knowledge of local language])
(* local refers to the treatment of the study-relevant tendon)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
OSTENIL® TENDON
2 injections of sodium hayluronate 2 % (40 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval. |
OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of pain intensity 3 months after end of treatment compared to baseline (visual analogue scale)
時間枠:Baseline compared to week 12 after the end of treatment.
|
Evaluation of pain intensity by the patient on a 100 mm visual analogue scale. 100 mm equals the worst pain. |
Baseline compared to week 12 after the end of treatment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
機器または申請手順との(可能性のある/可能性のある)因果関係を伴う有害事象の発生率
時間枠:治療終了後24週目まで。
|
治療終了後24週目まで。
|
|
|
機器または申請手順との(可能性のある/可能性のある)因果関係を伴う重篤な有害事象の発生率
時間枠:治療終了後24週目まで。
|
治療終了後24週目まで。
|
|
|
重大インシデント(と思われる)の発生状況
時間枠:治療終了後24週目まで。
|
治療終了後24週目まで。
|
|
|
デバイスの欠陥の発生率
時間枠:治療終了後24週目まで。
|
治療終了後24週目まで。
|
|
|
Change of Upper -/ Lower Extremity Functional Scale compared to baseline
時間枠:Baseline compared to week 1 as well as weeks 4, 12 and 24 after the end of treatment.
|
Indication specific patient questionnaire to assess effectiveness of treatment on a 5-point Likert scale (range: 0 = extreme difficulty to perform activity to 4 = no difficulty). |
Baseline compared to week 1 as well as weeks 4, 12 and 24 after the end of treatment.
|
|
Change of pain intensity compared to baseline (visual analogue scale)
時間枠:Baseline compared to week 1 as well as weeks 4 and 24 after the end of treatment.
|
Evaluation of pain intensity by the patient on a 100 mm visual analogue scale. 100 mm equals the worst pain. |
Baseline compared to week 1 as well as weeks 4 and 24 after the end of treatment.
|
|
Change of patient-reported outcome measures (PROM)
時間枠:Baseline (except satifaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.
|
Patient questionnaire to assess the following aspects (100 mm visual analogue scale; 100 mm equals a worse outcome): pain, global and tendon-associated quality of life, daily activities, clinical global impression, mobility and satisfaction with treatment (note: not assessed at baseline) |
Baseline (except satifaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.
|
|
Change of investigator-reported outcome measures
時間枠:Baseline (except satisfaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.
|
Investigator inquiry to record the perception of the physician of the following aspects (100 mm visual analogue scale; 100 mm equals a worse outcome): clinical global impression regarding the clinical severity of the tendinopathy and satisfaction with the treatment (note: not assessed at baseline) |
Baseline (except satisfaction with treatment), week 1 and weeks 4, 12 and 24 after the end of treatment.
|
|
Degree of tendinopathy
時間枠:Baseline, week 1 and weeks 4, 12 and 24 after the end of treatment
|
Evaluation of tendinopathy symptoms by the patient by rating tendon pain in the context of a patient-defined task that usually elicits pain (4 stages; 4 equals a worse outcome) |
Baseline, week 1 and weeks 4, 12 and 24 after the end of treatment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Olaf Neubert, Dr. med.、Orthopädie am Kiesteich
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。